Xenome raises funds, inks collaboration pact

Peptide-developer Xenome has signed a collaboration deal with Amylin Pharmaceuticals to develop novel peptide therapeutics for a range of metabolic and musculoskeletal diseases. Australia's Xenome separately announced that Amylin is making a $5 million equity investment in the company, part of a $10 million financing package.

- see the release on the development deal
- check out this release on the financing

Related Articles:
Psychogenics, Amylin create new development company. Report
Amylin reports weight-loss success with Symlin. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.